CBDV, or cannabidivarin, is among the most discreet cannabinoids on the consumer market. People talk about it little, you rarely see it explicitly sold — yet it's one of the most active cannabinoids in pharmaceutical research since 2020. British company GW Pharmaceuticals (acquired by Jazz Pharmaceuticals) has dedicated several clinical programmes to it, and major scientific publications have appeared. Here's why this molecule deserves attention.

What is CBDV

CBDV shares a very close molecular structure with CBD: same architecture, but with a propyl chain (3 carbons) instead of CBD's characteristic pentyl chain (5 carbons). This seemingly minor difference still alters the molecule's interactions with biological systems noticeably.

Like CBD, CBDV is non-psychoactive. It doesn't significantly bind to CB1 receptors of the endocannabinoid system — those involved in THC's psychotropic effects. It mainly acts on other receptors and systems (TRPV1, TRPA1, and certain ion channels) that play a role in perception and tissue regulation.

Why labs are interested

CBDV has been the subject of clinical research programmes, notably in the neurological domain. Without going into specific indications (which fall outside the French CBD editorial framework), we can note the molecule presents an original pharmacological profile, distinct from CBD despite chemical kinship. That makes it a prime candidate for pharmaceutical research, where molecular differentiation is an important intellectual property asset.

For the general public, CBDV's commercial interest remains more discreet than CBN or CBG. Few products are explicitly labelled « rich in CBDV ». When CBDV appears, it's typically in full spectrum oils whose complete cannabinoid profile is documented — without the molecule necessarily being the main marketing criterion.

Natural concentrations

CBDV is naturally found in certain hemp varieties, mainly at moderate concentrations (typically 0.5 to 2% of dry weight in standard CBD flowers). Like THCV, it's more present in genetics of equatorial and African origin — tropical varieties whose chemical diversity is more pronounced than that of modern European genetics selected for CBD.

CBDV-dominant lines have been developed by some specialised breeders but remain rare in European cultivation. Most CBDV present in products marketed in France appears in the natural profile of full spectrum flowers, without specific commercial valuation.

Legal status in France

CBDV is legal in France under the general industrial hemp framework: THC strictly below 0.3% in finished product, plant from authorised varieties, no therapeutic claims. No specific decree has separately regulated CBDV as of writing.

As for other minor cannabinoids, the situation may evolve. The French legislator closely tracks this category. To date, marketing products naturally containing CBDV remains authorised under the general framework.

In what forms to find CBDV

• Full spectrum flowers — CBDV appears naturally in the cannabinoid profile of many CBD flowers, at variable rates. Favour complete certificates of analysis to verify presence.
• « Broad profile » full spectrum oils — extracts where the complete profile is valued. CBDV is among documented cannabinoids.
• CBDV isolates — uncommon commercially, mainly used in research or specific formulations.

Our recommendation at Horus stays consistent with that for other minor cannabinoids: favour flowers and full spectrum where CBDV sits in its natural context, rather than seeking maximum isolation.

Precautions and compliance

CBDV isn't a medicine and isn't authorised therapeutically in France. If you're on treatment, talk to your doctor before any use of products containing this molecule. Like all cannabinoids, CBDV isn't recommended for pregnant or breastfeeding women, or minors.

On neurological topics in particular — where clinical research on CBDV is most active — any form of self-medication is strongly discouraged. Ongoing clinical trials use precise doses, in controlled frameworks, with strict medical follow-up. Products marketed in France don't provide these guarantees.

To explore other minor cannabinoids: CBN, evening-leaning, CBG, the mother molecule, CBC and the entourage effect, emerging THCV. To understand strains: Permanent Marker.

Frequently asked questions

Is CBDV psychoactive?

No. Like CBD, it doesn't significantly bind to CB1 receptors and doesn't trigger THC's characteristic cognitive effects.

What's the concrete difference between CBD and CBDV?

Very close molecular structure, but a shorter carbon chain. Distinct pharmacological profile on certain receptors, without us being able to say one « replaces » the other. Complementarity is more relevant than opposition.

Can you find it in a classic CBD oil?

Yes, in small amounts. Most full spectrum oils from European varieties contain CBDV at residual rates. For useful concentrations, prefer oils whose certificate of analysis precisely documents the complete cannabinoid profile.

Is CBDV studied for therapeutic applications?

Yes, as part of clinical research programmes conducted by pharmaceutical labs. These programmes are strictly separate from commercial hemp products you can buy in shops. No CBDV product sold in France has a therapeutic vocation.

Is CBDV expensive?

When present in its natural context (full spectrum flower, broad-spectrum oil), it doesn't significantly increase price. When valued as concentrate or isolate, the price can be substantially higher than generic CBD.